Overview

Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

Status:
Completed
Trial end date:
2020-03-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether combination therapy of irinotecan with AZD1775 is safe and effective in treating mutated metastatic colorectal cancer patients.
Phase:
Phase 1
Details
Lead Sponsor:
New York University School of Medicine
NYU Langone Health
Collaborator:
AstraZeneca
Treatments:
Adavosertib
Camptothecin
Irinotecan